<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442908</url>
  </required_header>
  <id_info>
    <org_study_id>SF-K002</org_study_id>
    <nct_id>NCT02442908</nct_id>
  </id_info>
  <brief_title>Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in COPD Cachexia</brief_title>
  <official_title>A 12-Week, Randomised, Placebo Controlled, Multi-Centre, Parallel Group Study Assessing the Safety and Tolerability of Nutrifriend Cachexia (Non-Complete Dietary Formula) in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smartfish AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smartfish AS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SF-K002 is a pilot study in patients with moderate to severe COPD suffering from involuntary
      weight loss. The study is 12 weeks, double-blinded, placebo controlled and the main objective
      is to study the safety and tolerability of Nutrifriend Cachexia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 12-week, randomised, parallel group, placebo controlled, multi-centre study.
      The primary objective is to evaluate the safety and tolerability of Nutrifriend Cachexia in
      patients with COPD. The secondary objectives of the study are to evaluate effects on body
      composition, muscle function, daily activity, inflammation, lung function, compliance,
      appetite and Quality of Life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability assessed by (adverse events, concomitant medication and laboratory markers) of Nutrifriend Cachexia in patients with COPD</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition assessed by fat mass and lean body mass (LBM)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition assessed by weight, BMI and waist &amp; calf circumference</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function assessed by 6 minute walking test</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function assessed by grip strength</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function assessed by walking distance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>12 weeks</time_frame>
    <description>IL-6, IL-8, TNF-alpha, CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic markers</measure>
    <time_frame>12 weeks</time_frame>
    <description>Glucose, insulin, cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL assessed by COPD Assessment Test (CAT)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL assessed by COPD Clinical Questionnaire (CCQ)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL assessed by St. George Respiratory Questionnaire for COPD patients (SGRQ C)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL assessed by Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL assessed by Nutrition Appetite Questionnaire (CNAQ)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance assessed by Drinks consumed</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance assessed by vitamin D levels</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance assessed by Omega-3 incorporation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>COPD</condition>
  <condition>Cachexia</condition>
  <arm_group>
    <arm_group_label>NF Cachexia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An isocaloric placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutrifriend Cachexia</intervention_name>
    <description>2 daily for 12 weeks</description>
    <arm_group_label>NF Cachexia</arm_group_label>
    <other_name>NFCax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Isocaloric placebo</intervention_name>
    <description>2 daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placobo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;50 years

          -  Moderate to severe COPD patients with forced expiratory volume (FEV1) of 30-60%

          -  Involuntary weight loss &lt;10%

          -  18 kg/m2 ≤ BMI ≤ 32 kg/m2

        Exclusion Criteria:

          -  Exacerbation of COPD within 3 months prior to screening

          -  Treatment with oral corticosteroids (&gt;5 mg/day) within 3 months prior to screening

          -  Treatment with anabolic steroids within 3 months prior to screening

          -  Current oxygen treatment or home ventilation therapy

          -  Change in smoking habits during the previous 6 months

          -  Major changes in COPD maintenance treatment within 3 months prior to screening

          -  Other cachectic disorders such as cancer, renal or hepatic disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ladulaas kliniska studier</name>
      <address>
        <city>Borås</city>
        <zip>50630</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmasite</name>
      <address>
        <city>Helsingborg</city>
        <zip>25220</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmasite</name>
      <address>
        <city>Malmö</city>
        <zip>21152</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A+ Science City Site</name>
      <address>
        <city>Stockholm</city>
        <zip>11157</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1002/jcsm.12228/abstract;jsessionid=8E0C9717131FC3B85669192A0E4F08AB.f02t03</url>
    <description>Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

